Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
Atavistik Bio, Inc
Compass Therapeutics
Eli Lilly and Company
Whitehawk Therapeutics, Inc.
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
AstraZeneca
Alterome Therapeutics, Inc.
Boehringer Ingelheim
Eli Lilly and Company
BeOne Medicines
Whitehawk Therapeutics, Inc.
Eli Lilly and Company
Accent Therapeutics
Seagen Inc.
AbbVie
Context Therapeutics Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
SEED Therapeutics, Inc.
TORL Biotherapeutics, LLC
Normunity AccelCo, Inc.
BioNTech SE
NiKang Therapeutics, Inc.
USWM, LLC (dba US WorldMeds)
IDEAYA Biosciences
MacroGenics
Cogent Biosciences, Inc.
SystImmune Inc.
Pheon Therapeutics
Solve Therapeutics
MOMA Therapeutics
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Eli Lilly and Company
Shanghai Best-Link Bioscience, LLC
Seagen Inc.
Fusion Pharmaceuticals Inc.
Risen (Suzhou) Pharma Tech Co., Ltd.
GlaxoSmithKline
Sairopa B.V.
Fate Therapeutics
NextCure, Inc.
NeoTX Therapeutics Ltd.
Blueprint Medicines Corporation
Radiopharm Theranostics, Ltd
SystImmune Inc.
Mersana Therapeutics
Incyte Corporation
NiKang Therapeutics, Inc.